ANVS - NYSE
Annovis Bio, Inc.
$2.60
+0.78%Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
At a Glance
Live SnapshotNo Investing Cash Flow Data
ANVS has not reported any investing cash flow values in the available annual periods.
Annovis Bio, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Annovis Bio, Inc. Cash Flow Statement
ANVS • NYSE
| Annovis Bio, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||
-28.9B | -24.6B | -56.2M | -25.3M | -14.5M | -5.5M | -991K | -713.9K | -682.3K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.2M | 0.0 | 0.0 | |
1.8B | 3.8B | 4.6M | 9.2M | 4.7M | 1.9M | 8.5K | 82.7K | 48.5K | |
1.4B | -1.1B | 11.8M | 0.0 | 0.0 | 27K | 84.4K | 85.4K | 11.6K | |
1.6M | 681.7K | -228.6K | -1.1M | 657.3K | -400.7K | 421.5K | 72.5K | 96.4K | |
-25.6B | -21.9B | -40M | -17.3M | -9.1M | -4M | -476.5K | -558.6K | -537.5K | |
INVESTING ACTIVITIES | |||||||||
FINANCING ACTIVITIES | |||||||||
34.6M | 18.7M | 16.9M | 4.6K | 46.6M | 9.2K | 0.0 | 2.8K | 8.5K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12M | 530K | 0.0 | 0.0 | |
34.6B | 26.7B | 458.4K | 0.0 | 95.1K | 0.0 | -86.9K | 246.4K | 332.5K | |
34.6B | 26.7B | 17.3M | 4.6K | 46.7M | 12M | 443.1K | 246.4K | 332.5K | |
CASH FLOW SUMMARY | |||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.0 | 0.0 | 0.0 | 0.0 | |
9B | 4.8B | -22.6M | -17.3M | 37.6M | 8.1M | -33.5K | -312.2K | -205K | |
10.6B | 5.8B | 28.4M | 45.7M | 8.1M | 1.9K | 35.3K | 347.5K | 552.5K | |
19.5B | 10.6B | 5.8M | 28.4M | 45.7M | 8.1M | 1.9K | 35.3K | 347.5K | |
-25.6B | -21.9B | -40M | -17.3M | -9.1M | -4M | -476.5K | -558.6K | -537.5K |
SEC Filings
ANVS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 13, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 28, 2026 | January 28, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 28, 2025 | October 26, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 14, 2025 | October 10, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 29, 2025 | September 25, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 15, 2025 | August 11, 2025 | 2025 |
Related Guides
Continue your ANVS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.